Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

Investors should also remember that disruptive cycles tend to face skepticism before the fundamentals take over, and this AI ...

Wedbush analyst Laura Chico maintained a Buy rating on Astria Therapeutics (ATXS – Research Report) today and set a price target of $28.00. The ...

In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on Geron (GERN – Research Report), with a price target of ...

Tech stocks like Nvidia tended to rise on the inflation news as odds of the Federal Reserve (Fed) cutting interest rates are now moved up on the calendar. The NASDAQ Composite advanced 1.2%, but the ...

Just days after saying Tesla Inc.’s recent stock selloff was overdone, Wedbush analyst Dan Ives, a well-known tech analyst ...

Tesla’s stock began rising from the opening Tuesday after Trump posted overnight on his Truth Social platform that Musk was “putting it on the line” to help the country. Trump claimed in the post that ...

Shares of Tesla slid again Monday as confidence in Elon Musk’s electric car company continues to disintegrate following a ...

Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research ...

Elon Musk’s role in the Trump administration is complicating his business ventures, as the tech billionaire pushes forward ...

Markets are still under a great deal of pressure. All thanks to more tariffs on Canada, Mexico, China and inflation threats, ...

The TSLA stock was up close to 5% on Tuesday. In the past one month, the stock has gone down around 30%. Wedbush Securities ...